We have repeatedly in our publications considered the opportunities available to biotechnology students within the framework of specialized subject studies. It was no exception to master such disciplines as “Technologies of Microbial Synthesis of Medicines” and “Industrial Technology of Medicines,” as future biotechnology specialists in their third year of study did not miss the opportunity to take advantage of the invitation to attend a guest lecture from a former student of our university, Anastasia Bondarenko. The meeting took place as usual in online mode on the Zoom platform.
Currently, the former NUFT graduate works in the registration department of Ukraine’s leading pharmaceutical company – Arterium Corporation, meaning she is directly involved in the registration of medicines. At the beginning of her career, Anastasia gained her professional experience working as a process engineer at another pharmaceutical company, where she dealt with the development of technological regulations, production formulations, technological instructions, and packaging instructions.
The topic of this online lecture was “General Concept of State Provision of Quality Assurance for Medicines.” The main points that the lecturer detailed were:
- WHO strategy on ensuring the quality of medicines;
- Good pharmaceutical practices GxP.
The specialist shared all the nuances of the development, research, and implementation of medicinal substances and the requirements that cover all stages of the life cycle of medicines. The guest discussed what pharmaceutical development really is, proper clinical and preclinical research, as well as the concept of good manufacturing practice (GMP) and its main requirements.
Students, as before, gladly shared their impressions after the end of the conference:
Zabrodska Yuliana, having listened to the lecture, expressed her gratitude for the interesting material as follows: “I want to thank the speaker from Arterium company, who helped deepen our already acquired knowledge and added more new and interesting information that we need for our future profession. At this conference, they discussed the concept of state provision of quality assurance for medicines, namely about standard good practice, its features, as well as the relationship of Good Pharmaceutical Practices in ensuring the quality of medicines. The speaker answered questions concretely and comprehensively, which made it possible to learn more about ensuring the quality of medicines. Thank you.”
Vodyanytska Anastasia noted: “Today’s lecture was truly interesting for us, which included a discussion of WHO’s strategy on ensuring the quality of medicines and good pharmaceutical practices GxP. We learned that the WHO concept of medicine quality includes efficacy and safety of medicine use, compliance with specification requirements, and that production must comply with GMP rules. All these are the most important rules that everyone should know.
It was also very interesting to hear information about the relationship of Good Pharmaceutical Practices in ensuring the quality of medicines. Everything starts with pharmaceutical development, whose purpose is to create a medicine of appropriate quality and substantiate the process of its production.
It was very interesting to listen and learn something new for ourselves. All those present really enjoyed the presentation, because after the lecture many different questions were asked. Also, I would like to thank the teachers for the opportunity to learn something new for ourselves!”
Parfenyuk Maria also shared her impressions: “It was extremely interesting to listen to a lecture about how the quality of medicines is ensured in our country. The speaker outlined in the most informative and accessible form what GxP is and what stages it consists of. During the presentation, we recalled what the general scheme of ensuring the quality of medicines looks like, what parts the Guidance ST-N MOH 42-4.0:2020 “Medicines. Good Manufacturing Practice” consists of, its main innovations.
The lecturer outlined the main nuances and features of each stage of the life cycle of a medicine, as well as key points regarding the main GMP requirements. It was very interesting to learn how the procedure of clinical trials is conducted at one of the leading enterprises of Arterium Corporation.
This presentation was especially useful for our course, since we have already considered such issues during this semester, so this lecture helped us organize our knowledge, which means we are prepared for the session.”
Marta Shulha summed it up as follows: “It was very interesting and useful, even though from the discipline “Regulatory Support of Biotechnological Production” we already knew some concepts and key points, but listening to a practicing professional with work experience is quite different. We heard and learned a lot of new information, because this topic is inextricably linked with our future profession.
At the end of the meeting, the lecturer gladly answered all our questions, providing clear and competent explanations. After such conferences, the desire to study and develop becomes ever greater.”
Such sincere and even somewhat emotional feedback from young biotechnologists is evidence of the practical value of meetings in this format. Therefore, it makes sense to continue the practice of guest lectures and expand the circle of invited specialists and conference topics.
So, until the next interesting meetings in the next academic year. And we wish our students success in passing the session and gaining strength to overcome new educational milestones in professional development as a biotechnologist!























